Ioannis Parodis

Artiklar i tidskrifter

• Hoff, L. S. , Ravichandran, N. , Shinjo, S. K. , Day, J. , Sen, P. , Junior, J. G. , Lilleker, J. B. , Joshi, M. & et al. (2023). COVID-19 severity and vaccine breakthrough infections in idiopathic inflammatory myopathies, other systemic autoimmune and inflammatory diseases, and healthy controls: a multicenter cross-sectional study from the COVID-19 Vaccination in Autoimmune Diseases (COVAD) survey. Rheumatology International, 43 (1), 47-58.
• Giannopoulou, N. , Gupta, L. , Andreoli, L. , Lini, D. , Nikiphorou, E. , Aggarwal, R. , Agarwal, V. , Parodis, I. & et al. (2023). COVID-19 vaccine safety during pregnancy in women with systemic lupus erythematosus. Autoimmunity Reviews.
• Sen, P. , Parodis, I. , Agarwal, V. , Aggarwal, R. , Gupta, L. & COVAD study group, -. (2023). Vaccine hesitancy decreases, long term concerns remain in myositis, rheumatic disease patients: A comparative analysis of the COVAD surveys. Rheumatology.
• Parodis, I. , Gomez, A. , Lindblom, J. , Chow, J. W. , Sjöwall, C. , Sciascia, S. & Gatto, M. (2022). B Cell Kinetics upon Therapy Commencement for Active Extrarenal Systemic Lupus Erythematosus in Relation to Development of Renal Flares: Results from Three Phase III Clinical Trials of Belimumab. International Journal of Molecular Sciences, 23 (22).
• Emamikia, S. , Gentline, C. , Enman, Y. & Parodis, I. (2022). CAN WE ENHANCE ADHERENCE TO MEDICATIONS IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS? RESULTS FROM A QUALITATIVE STUDY. Annals of the Rheumatic Diseases, 81 (Suppl. 1), 439-439.
• Sjöwall, C. & Parodis, I. (2022). Clinical Heterogeneity, Unmet Needs and Long-Term Outcomes in Patients with Systemic Lupus Erythematosus. Journal of Clinical Medicine, 11 (22).
• Fazal, Z. Z. , Sen, P. , Joshi, M. , Ravichandran, N. , Lilleker, J. B. , Agarwal, V. , Kardes, S. , Kim, M. & et al. (2022). COVAD survey 2 long-term outcomes: unmet need and protocol. Rheumatology International, 42 (12), 2151-2158.
• Gupta, L. , Hoff, L. S. , R, N. , Sen, P. , Katsuyuki Shinjo, S. , Day, J. , Lilleker, J. B. , Agarwal, V. & et al. (2022). COVID-19 SEVERITY AND VACCINE BREAKTHROUGH INFECTIONS IN IDIOPATHIC INFLAMMATORY MYOPATHIES, OTHER SYSTEMIC AUTOIMMUNE AND INFLAMMATORY DISEASES, AND HEALTHY INDIVIDUALS: RESULTS FROM THE COVID-19 VACCINATION IN AUTOIMMUNE DISEASES (COVAD) STUDY.. Annals of the Rheumatic Diseases, 81 (Suppl. 1), 334-336.
• Sen, P. , Gupta, L. , Lilleker, J. B. , Aggarwal, V. , Kardes, S. , Milchert, M. , Gheita, T. , Salim, B. & et al. (2022). COVID-19 vaccination in autoimmune disease (COVAD) survey protocol. Rheumatology International, 42 (1), 23-29.
• R., N. , Parodis, I. , Joshi, M. , Sen, P. , Lindblom, J. , Agarwal, V. , Lilleker, J. B. , Tan, A. L. & et al. (2022). COVID-19 vaccination in autoimmune diseases (COVAD) Study: vaccine safety and tolerance in rheumatoid arthritis. Rheumatology.
• Gil-Vila, A. , Naveen, R. , Selva-O'Callaghan, A. , Sen, P. , Nune, A. , Gaur, P. S. , Gonzalez, R. A. , Lilleker, J. B. & et al. (2022). COVID-19 Vaccination In Autoimmune Diseases (COVAD) Study: Vaccine Safety In Idiopathic Inflammatory Myopathies. Muscle and Nerve, 66 (4), 426-437.
• Sen, P. , R., N. , Nune, A. , Lilleker, J. B. , Agarwal, V. , Kardes, S. , Kim, M. , Day, J. & et al. (2022). COVID-19 vaccination-related adverse events among autoimmune disease patients: results from the COVAD study. Rheumatology, 62 (1), 65-76.
• Sen, P. , R, N. , Nune, A. , Lilleker, J. B. , Agarwal, V. , Kardes, S. , Kim, M. , Day, J. & et al. (2022). COVID-19 VACCINATION-RELATED ADVERSE EVENTS AMONG AUTOIMMUNE DISEASE PATIENTS: RESULTS FROM THE COVID-19 VACCINATION IN AUTOIMMUNE DISEASES (COVAD) STUDY. Annals of the Rheumatic Diseases, 81 (Suppl. 1), 966-967.
• Sciascia, S. , Roccatello, D. , Radin, M. , Parodis, I. , Yazdany, J. , Pons-Estel, G. & Mosca, M. (2022). Differentiating between UCTD and early-stage SLE: from definitions to clinical approach. Nature Reviews Rheumatology, 18, 9-21.
• Parodis, I. , Lindblom, J. , Toro-Dominguez, D. , Borghi, M. O. , Enman, Y. , Repsilber, D. , Mohan, C. , Alarcon-Riquelme, M. & et al. (2022). DRUG REPURPOSING FOR TREATING LUPUS NEPHRITIS BASED ON TRANSCRIPTOME PROFILING AND AUTOIMMUNITY-RELATED SEROLOGICAL MARKERS. Annals of the Rheumatic Diseases, 81 (Suppl. 1), 326-326.
• Parodis, I. , Gomez, A. , Chow, J. W. , Borg, A. , Lindblom, J. & Gatto, M. (2022). Early B Cell and Plasma Cell Kinetics Upon Treatment Initiation Portend Flares in Systemic Lupus Erythematosus: A Post-Hoc Analysis of Three Phase III Clinical Trials of Belimumab. Frontiers in Immunology, 13.
• Parodis, I. , Gomez, A. , Lindblom, J. , Chow, J. W. , Doria, A. & Gatto, M. (2022). Early Changes in B and Plasma Cell Subsets and Traditional Serological Markers as Predictors of SRI-4 Response to Therapy in Systemic Lupus Erythematosus. Frontiers in medicine, 9.
• Sciascia, S. , Parodis, I. & Karim, M. Y. (2022). Editorial: Clinical, Molecular and Adverse Responses to B-Cell Therapies in Autoimmune Disease. Frontiers in Immunology, 13.
• Lindblom, J. , Zetterberg, S. , Emamikia, S. , Borg, A. , von Perner, G. , Enman, Y. , Heintz, E. , Regardt, M. & et al. (2022). EQ-5D full health state after therapy heralds reduced hazard to accrue subsequent organ damage in systemic lupus erythematosus. Frontiers in Medicine, 9.
• Parodis, I. & Houssiau, F. A. (2022). From sequential to combination and personalised therapy in lupus nephritis: moving towards a paradigm shift?. Annals of the Rheumatic Diseases, 81 (1), 15-19.
• Grignaschi, S. , Cavagna, L. , Kim, M. , R, N. , Lilleker, J. B. , Sen, P. , Agarwal, V. , Kardes, S. & et al. (2022). HIGH FATIGUE SCORES IN PATIENTS WITH IDIOPATHIC INFLAMMATORY MYOPATHIES: A MULTIGROUP COMPARATIVE STUDY FROM THE COVAD E-SURVEY. Annals of the Rheumatic Diseases, 81 (Suppl. 1), 748-748.
• Dey, M. , Parodis, I. , Gupta, L. & COVAD Study Group, -. (2022). Higher risk of short term COVID-19 vaccine adverse events in myositis patients with autoimmune comorbidities: results from the COVAD study. Rheumatology.
• Emamikia, S. , Gentline, C. , Enman, Y. & Parodis, I. (2022). How Can We Enhance Adherence to Medications in Patients with Systemic Lupus Erythematosus? Results from a Qualitative Study. Journal of Clinical Medicine, 11 (7).
• Emamikia, S. , Oon, S. , Gomez, A. , Lindblom, J. , Borg, A. , Enman, Y. , Morand, E. , Grannas, D. & et al. (2022). Impact of remission and low disease activity on health-related quality of life in patients with systemic lupus erythematosus. Rheumatology, 61 (12), 4752-4762.
• Yoshida, A. , Kim, M. , Kuwana, M. , Naveen, R. , Makol, A. , Sen, P. , Lilleker, J. B. , Agarwal, V. & et al. (2022). Impaired physical function in patients with idiopathic inflammatory myopathies: results from the multicentre COVAD patient-reported e-survey. Rheumatology.
• Yoshida, A. , Kim, M. , Kuwana, M. , R, N. , Lilleker, J. B. , Sen, P. , Agarwal, V. , Kardes, S. & et al. (2022). IMPAIRED PROMIS PHYSICAL FUNCTION IN IDIOPATHIC INFLAMMATORY MYOPATHY PATIENTS: RESULTS FROM THE MULTICENTER COVAD PATIENT REPORTED E-SURVEY. Annals of the Rheumatic Diseases, 81 (Suppl. 1), 720-722.
• Hernández-Breijo, B. , Parodis, I. , Novella-Navarro, M. , Martínez-Feito, A. , Navarro-Compán, V. , Díaz-Almirón, M. , Pascual-Salcedo, D. , Balsa, A. & et al. (2022). Low Serum BAFF Concentration Is Associated with Response to TNF Inhibitors in Seropositive Patients with Rheumatoid Arthritis. Journal of Clinical Medicine, 11 (17).
• Gomez, A. , Parodis, I. & Sjöwall, C. (2022). OBESITY AND TOBACCO SMOKING ARE INDEPENDENTLY ASSOCIATED WITH POOR PATIENT-REPORTED OUTCOMES IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS FROM A SWEDISH TERTIARY REFERRAL CENTRE. Annals of the Rheumatic Diseases, 81 (Suppl. 1), 1402-1402.
• Stamm, T. , Parodis, I. & Studenic, P. (2022). Patient-reported outcomes with anifrolumab in patients with systemic lupus erythematosus. Lancet Rheumatology, 4 (3), E157-E159.
• R., N. , Nikiphorou, E. , Joshi, M. , Sen, P. , Lindblom, J. , Agarwal, V. , Lilleker, J. B. , Tan, A. L. & et al. (2022). Safety and tolerance of vaccines against SARS-CoV-2 infection in systemic lupus erythematosus: results from the COVAD study.. Rheumatology.
• Parodis, I. , Gomez, A. , Tsoi, A. , Chow, J. W. , Pezzella, D. , Girard, C. , Stamm, T. , Boström, C. & et al. (2022). SYSTEMATIC LITERATURE REVIEW TO INFORM THE EULAR TASK FORCE FOR RECOMMENDATIONS/POINTS TO CONSIDER FOR THE NON-PHARMACOLOGICAL MANAGEMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS AND SYSTEMIC SCLEROSIS. Annals of the Rheumatic Diseases, 81 (Suppl. 1), 1098-1099.
• Lindblom, J. , Toro-Dominguez, D. , Borghi, M. O. , Iacobaeus, E. , Enman, Y. , Repsilber, D. , Mohan, C. , Alarcon-Riquelme, M. & et al. (2022). TRANSCRIPTOME PROFILING AND AUTOIMMUNITY-RELATED SEROLOGICAL MARKERS IDENTIFY TP53 AND C3AR AS DRUG TARGETS IN NEUROPSYCHIATRIC SYSTEMIC LUPUS ERYTHEMATOSUS. Annals of the Rheumatic Diseases, 81 (Suppl. 1), 326-326.
• Aoude, M. , Gupta, L. , Hmamouchi, I. , Grignaschi, S. , Cavagna, L. , Kim, M. , R, N. , Lilleker, J. B. & et al. (2022). TREATMENT PATTERNS OF IDIOPATHIC INFLAMMATORY MYOPATHIES: RESULTS FROM AN INTERNATIONAL COHORT OF OVER 1,400 PATIENTS. Annals of the Rheumatic Diseases, 81 (Suppl. 1), 105-106.
• Parodis, I. , Tamirou, F. & Houssiau, F. A. (2022). Treat-to-Target in Lupus Nephritis: What is the Role of the Repeat Kidney Biopsy?. Archivum Immunologiae et Therapiae Experimentalis, 70 (1).
• Sen, P. , Lilleker, J. B. , Agarwal, V. , Kardes, S. , Milchert, M. , Gheita, T. , Salim, B. , Velikova, T. & et al. (2022). Vaccine hesitancy in patients with autoimmune diseases: Data from the coronavirus disease-2019 vaccination in autoimmune diseases study. Indian Journal of Rheumatology, 17 (2), 188-191.
• Parodis, I. , Gomez, A. , Lindblom, J. , Borg, A. , Emamikia, S. & Gatto, M. (2021). Associations Between Early Changes in Circulating B Cell Subsets and Severe Flare in Systemic Lupus Erythematosus: Results from Three Phase III Trials of Belimumab. Arthritis & Rheumatology, 73 (Suppl. 9), 2699-2700.
• Hernández-Breijo, B. , Navarro-Compán, V. , Plasencia-Rodríguez, C. , Parodis, I. , Gehin, J. E. , Martínez-Feito, A. , Novella-Navarro, M. , Mezcua, A. & et al. (2021). BAFF predicts immunogenicity in older patients with rheumatoid arthritis treated with TNF inhibitors. Scientific Reports, 11 (1).
• Parodis, I. , Andersson, L. , Durning, S. J. , Hege, I. , Knez, J. , Kononowicz, A. A. , Lidskog, M. , Petreski, T. & et al. (2021). Clinical Reasoning Needs to Be Explicitly Addressed in Health Professions Curricula: Recommendations from a European Consortium. International Journal of Environmental Research and Public Health, 18 (21).
• Parodis, I. , Gomez, A. , Lindblom, J. , Borg, A. , Emamikia, S. & Gatto, M. (2021). Early Increase in Circulating Memory B Cells Portends Clinical Response to Treatment in Pooled Data from Three Phase III Trials of Belimumab. Arthritis & Rheumatology, 73 (Suppl. 9), 2695-2696.
• Hernandez-Breijo, B. , Parodis, I. , Plasencia-Rodríguez, C. , Díaz-Almirón, M. , Martínez-Feito, A. , Novella-Navarro, M. , Pascual-Salcedo, D. & Balsa, A. (2021). Serum B Cell Activating Factor Reflects Good EULAR Response to TNF Inhibition in Patients with Rheumatoid Arthritis. Arthritis & Rheumatology, 73 (Suppl. 9), 2586-2588.
• Emamikia, S. , Oon, S. , Gomez, A. , Lindblom, J. , Borg, A. , Enman, Y. , Morand, E. , Grannas, D. & et al. (2021). The Impact of Remission and Low Disease Activity Attainment on Health-related Quality of Life in Two Phase III Clinical Trials of Belimumab in Systemic Lupus Erythematosus. Arthritis & Rheumatology, 73 (Suppl. 9), 2604-2606.

Artiklar, forskningsöversikter

• Gomez, A. , Enman, Y. & Parodis, I. (2023). Impact of Belimumab on Patient-Reported Outcomes in Systemic Lupus Erythematosus: Insights from Clinical Trials and Real-World Evidence. Patient Related Outcome Measures, 14, 1-13.
• Parodis, I. , Gatto, M. & Sjöwall, C. (2022). B cells in systemic lupus erythematosus: Targets of new therapies and surveillance tools. Frontiers in Medicine, 9.
• Lindblom, J. , Mohan, C. & Parodis, I. (2022). Biomarkers in Neuropsychiatric Systemic Lupus Erythematosus: A Systematic Literature Review of the Last Decade. Brain Sciences, 12 (2).
• Palazzo, L. , Lindblom, J. , Mohan, C. & Parodis, I. (2022). Current Insights on Biomarkers in Lupus Nephritis: A Systematic Review of the Literature. Journal of Clinical Medicine, 11 (19).
• Lindblom, J. , Mohan, C. & Parodis, I. (2022). Diagnostic, predictive and prognostic biomarkers in systemic lupus erythematosus: current insights. Current Opinion in Rheumatology, 34 (2), 139-149.
• Gomez, A. & Parodis, I. (2022). Do biological agents improve health-related quality of life in patients with systemic lupus erythematosus? Results from a systematic search of the literature. Autoimmunity Reviews, 21 (11).
• Parodis, I. & Studenic, P. (2022). Patient-Reported Outcomes in Systemic Lupus Erythematosus: Can Lupus Patients Take the Driver's Seat in Their Disease Monitoring?. Journal of clinical medicine, 11 (2).
• Dey, M. , Parodis, I. & Nikiphorou, E. (2021). Fatigue in Systemic Lupus Erythematosus and Rheumatoid Arthritis: A Comparison of Mechanisms, Measures and Management. Journal of clinical medicine, 10 (16).